Loading clinical trials...
Loading clinical trials...
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Conditions
Interventions
LEE-011
Fulvestrant
+1 more
Locations
13
United States
University of Alabama at Birmingham (UAB)
Birmingham, Alabama, United States
Northside Hospital, Inc.
Atlanta, Georgia, United States
Northwestern Medical Hospital
Chicago, Illinois, United States
The University of Kansas Cancer Center
Westwood, Kansas, United States
Northwell Health/Monter Cancer Center
Lake Success, New York, United States
NYU Langone Medical Center
New York, New York, United States
Start Date
March 1, 2016
Primary Completion Date
January 4, 2022
Completion Date
January 4, 2022
Last Updated
December 6, 2024
NCT05468034
NCT05969860
NCT07347600
NCT06492759
NCT03448926
NCT07085767
Lead Sponsor
Melissa K Accordino
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions